KRT19 and breast carcinoma: Conduct in vivo validation using xenograft models: Xenograft models of the four breast cancer cell lines (MDA-MB-231, MDA-MB-468, MCF7, and T47D) will be established in immunocompromised mice to assess CuNPs’ biodistribution, therapeutic efficacy, and impact on KRT19 expression in a physiological context.